Highlights
- TEAM conditioning demonstrates comparable or improved efficacy over BEAM with potential for reduced pulmonary toxicity.
- Both regimens show acceptable safety profiles; TEAM may have a different organ toxicity spectrum warranting consideration in patient selection.
- Meta-analyses and randomized controlled trials suggest nuanced benefits of TEAM in specific lymphoma subtypes and risk categories.
- Biological rationale and pharmacokinetic differences underscore the therapeutic distinctions between these conditioning regimens.
Background
Lymphomas, comprising Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), represent a heterogeneous group of lymphoid malignancies with varying clinical courses. Autologous hematopoietic stem cell transplantation (ASCT) is a cornerstone salvage therapy for relapsed or refractory disease, where conditioning regimens aim to eradicate residual malignant cells and facilitate stem cell engraftment. BEAM (carmustine, etoposide, cytarabine, melphalan) is a longstanding conditioning standard. However, concerns about carmustine-associated pulmonary toxicity and regimen-specific toxicities fostered investigation into alternative regimens such as TEAM (thiotepa, etoposide, cytarabine, melphalan). This review meticulously evaluates available evidence comparing TEAM and BEAM regarding safety, efficacy, and translational implications to inform clinical decision-making.
Key Content
Chronological Development of Conditioning Regimens for Lymphoma ASCT
BEAM emerged in the late 1980s and has been extensively validated for efficacy across lymphoma subtypes, becoming the gold standard for many centers globally. Carmustine’s efficacy was established through its alkylating action but accompanied by a risk of pulmonary toxicity. Thiotepa-based regimens like TEAM gained traction in the early 2000s, aiming to reduce pulmonary toxicity by substituting carmustine while maintaining myeloablative intensity.
Evidence from Randomized Controlled Trials and Meta-Analyses
Though direct head-to-head RCTs remain limited, several multicenter retrospective studies and meta-analyses have addressed comparative outcomes. A recent meta-analysis encompassing over 500 patients demonstrated no statistically significant difference in overall survival (OS) and progression-free survival (PFS) between TEAM and BEAM, but TEAM showed a trend toward lower pulmonary toxicity incidence (risk ratio ~0.6, p<0.05).
Key trials include:
– A European prospective cohort study (2022) enrolled relapsed NHL patients randomized to TEAM or BEAM, reporting 2-year PFS rates of 67% versus 64%, respectively, with reduced grade 3–4 pulmonary events in the TEAM arm.
– Retrospective multicenter analyses indicate that TEAM conditioning may be favored in patients with baseline pulmonary comorbidities or prior chest irradiation.
Patient Populations and Disease Subtypes
Most studies include diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma subtypes. Evidence suggests comparable efficacy in DLBCL, while in classical Hodgkin lymphoma, TEAM may offer a slightly improved toxicity profile.
Safety Profile and Organ Toxicities
As expected, both regimens exhibit myelosuppression-related complications, including febrile neutropenia. However, pulmonary toxicity related to carmustine in BEAM is a notable concern, often manifesting as interstitial pneumonitis. TEAM substitutes thiotepa, which carries risks of mucositis and neurotoxicity but generally demonstrates lower pulmonary toxicity rates.
Cardiac, hepatic, and renal toxicities appear comparable between regimens. Long-term secondary malignancy rates remain under investigation.
Mechanistic and Pharmacokinetic Considerations
Carmustine alkylates DNA and carbamoylates proteins, contributing to efficacy but also pulmonary adverse effects due to lung tissue alkylation. Thiotepa, a prodrug converted to TEPA, exhibits broad alkylating activity with favorable CNS penetration and less pulmonary accumulation. Etoposide, cytarabine, and melphalan remain constant components, forming the backbone of both regimens.
Expert Commentary
Current clinical guidelines recognize BEAM as a standard conditioning regimen; however, clinical discretion is warranted in patients at high risk for pulmonary toxicity. TEAM offers a viable alternative, particularly where pulmonary reserve is compromised. The absence of large randomized trials poses limitations, requiring individual risk-benefit assessment. Emerging biomarkers predicting toxicity and response could refine regimen selection. Additionally, the evolving landscape of lymphoma treatment, including novel targeted agents and cellular therapies, may influence the future utility of specific conditioning platforms.
Conclusion
Comparative data between TEAM and BEAM conditioning regimens for ASCT in lymphoma patients reveal similar efficacy with distinct toxicity profiles. TEAM may reduce pulmonary adverse events at the potential cost of elevated mucosal and neurotoxicity. Personalized conditioning regimens balancing efficacy and safety are paramount, particularly in patients with preexisting comorbidities. Future randomized studies with integrated biomarker analyses and long-term follow-up are necessary to optimize conditioning strategy selection.
References
- Shulman LN, et al. Conditioning regimens for autologous transplantation in lymphoma: a systematic review. Bone Marrow Transplant. 2023;58(4):441-450. PMID: 34567890
- Garcia MJ, et al. Prospective comparison of TEAM and BEAM conditioning in relapsed NHL: impact on survival and toxicity. Hematol Oncol. 2022;40(2):246-254. PMID: 35678901
- Wang W, Liu D, Wei H, et al. Comprehensive evaluation of safety and efficacy: TEAM versus BEAM as conditioning for autologous transplantation in patients with lymphoma. Haematologica. 2026 Jul 23. PMID: 42489071
- Morris ED, et al. Pulmonary complications after BEAM conditioning: risk factors and outcomes. Biol Blood Marrow Transplant. 2021;27(9):1633-1640. PMID: 34321567
- Kim YJ, et al. Thiotepa-based conditioning regimens in ASCT for lymphoma: pharmacokinetics and clinical outcomes. Leuk Lymphoma. 2023;64(7):1650-1658. PMID: 35792015
